ArticleJHLT open2026

Exploring patient preferences regarding the use of combination therapy with endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitors (PDE5i).

Nicholas A Kolaitis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.